If there is clinical improvement and if a reticulocyte response is observed, the same amount may be given on alternate days for seven doses, then every three to four days for another two to three weeks
it is not approved in the US, EU or UK
Bottom Line Current research indicates that oral BPC-157 may be more suitable for gastrointestinal support, while injectable BPC-157 has been the primary focus in studies exploring recovery beyond the digestive tract
Search Peptide Dosage Guides Search 100+ research peptides for vial size, BAC water, dosing, frequency, and cycle length for 100+ research peptides, including BPC-157, TB-500, Semaglutide, and Retatrutide